✦ LIBER ✦

Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy

✍ Scribed by George A. Omura; W. Ralph Vogler; John Lefante; Harold Silberman; William Knospe; David Gordon; Rhonda Jarrell

Publisher: John Wiley and Sons
Year: 1982
Tongue: English
Weight: 651 KB
Volume: 49
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19820415)49:8<1530::aid-cncr2820490804>3.0.co;2-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized comparison of maintenance t

A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia-lymphoma group trial of the EORTC

✍ M. Hayat; U. Jehn; R. Willemze; C. Haanen; R. Zittoun; M. Monconduit; B. Lowenbe 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 624 KB

Treatment of acute myeloid leukemia with

Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long-term maintenance chemotherapy

✍ Dr. David Machover; Henry Rappaport; Léon Schwarzenberg; Jean-Louis Misset; Emma 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 660 KB

The authors developed a therapeutic regimen in which 33 patients aged I I to 61 years (mean 2 SE, 35.9 t 2.3 years) with acute myeloid leukemia (AML) were given intensive induction chemotherapy with Adriamycin (doxorubicin) (ADM), vincristine (VCR) and cytosine arabinoside (ARA-C). Twenty-nine of th

Treatment of de novo acute myelogenous l

Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts

✍ Valent, Peter ;Sillaber, Christian ;Geissler, Klaus ;Andreeff, Michael ;Tafuri, 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB

GM-CSF is a major regulator of myelopoiesis. Recombinant human GM-CSF (250 micrograms/m2 per day i.v.) was used prior to chemotherapy ("3 + 7" scheme) to recruit leukemic blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of